ca ovary dr. varun
DESCRIPTION
TRANSCRIPT
![Page 1: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/1.jpg)
CA OVARY
DR. VARUNMEDICAL ONCOLOGIST
RGCI DELHI
![Page 2: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/2.jpg)
• Epidemiology• Risk factors• Pathology and pathogenesis• Diagnosis• Screening• Staging
![Page 3: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/3.jpg)
INTRODUCTION• Ovarian cancer is one of the most treatable solid
tumors, as the majority will respond temporarily to surgery and cytotoxic agents.
• Tumors of epithelial, germ cell, or sex cord–stromal origin.– Epithelial - in postmenopausal women, – Germ cell tumors - in younger women, and – Sex cord–stromal tumors - at any age.
• 80- 90% of ovarian cancer is epithelial in origin.
![Page 4: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/4.jpg)
Burden of suffering• 5th most frequent cancer in women worldwide. • 5th leading cause of cancer death in women in
U.S. (after breast, lung, colon and pancreas)• MC cause of death arising from a female pelvic
malignancy.
• each year, in the US – 22,000 new cases of epithelial ovarian cancer – 15,460 deaths
![Page 5: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/5.jpg)
Name of Registry Leading Site 2nd Leading site 3rd leading site
Bangalore Breast Cervix Ovary
Barshi Expanded Cervix Breast Ovary
Bhopal Breast Cervix Ovary
Chennai Breast Cervix Ovary
Delhi Breast Cervix Ovary
Mumbai Breast Cervix Ovary
Barshi Rural Cervix Breast Esophagus
Cachar District Breast Cervix Gall bladder
Dibrugarh District Breast ESophagus Gall bladder
Kamrup District Breast Cervix Esophagus
FEMALE—LEADING SITE
![Page 6: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/6.jpg)
INDIAN DATA-- DELHI
![Page 7: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/7.jpg)
Trends in Cancer incidence-FemaleRegistry Leading site in 1982 Now(2006-2008)
Banglore Cervix Breast, Ovary(↑)
Bhopal Cervix Breast, Ovary(↑)
Chennai Cervix Breast, Ovary(↑)
Barshi Cervix Cervix, Lung(↑)
Delhi Cervix Breast, Ovary(3rd)GB(4th)
Mumbai Breast Breast, Lung(↑) Ovary(↑)
![Page 8: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/8.jpg)
• Overall 5-year survival rate is 45%
• The “silent killer”: asymptomatic in early stages– 75% diagnosed with advanced stage disease; 5-
year survival only 10-28%
• Woman’s lifetime risk of – developing sporadic epithelial ovarian cancer
• 1.7% in developed nations and 0.75% in India.
– dying from ovarian cancer is1.1%
![Page 9: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/9.jpg)
• ̴� 25% of ovarian tumors are malignant.
• Approximately 80 % of them are primary growths of the ovary.
• The remainder being secondary.
![Page 10: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/10.jpg)
• Median age at diagnosis – for sporadic - 60 years, – With a genetic predisposition (5-10%) - fifth
decade.
• only 10% to 15% - in premenopausal women
![Page 11: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/11.jpg)
Risk Factors
![Page 12: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/12.jpg)
![Page 13: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/13.jpg)
![Page 14: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/14.jpg)
BRCA Mutations
• Greater risk of developing ovarian cancer, • Overall they have superior outcomes
compared with patients who do not possess these mutations.
• Rubin 1996; Boyd 2000
• The theory behind this observation - same genetic defect that increases the risk of cancer prevents already-malignant cells from repairing the damage induced by agents such as platinum.
![Page 15: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/15.jpg)
HNPCC or Lynch Syndrome
• ~7% of hereditary ovarian cancer cases
• Responsible genes: Mismatch repair genes (MMR) including MLH1, MSH2, and MSH6
• Increased incidence of other adenocarcinomas, including stomach, small bowel, and bile duct malignancies (not breast)
![Page 16: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/16.jpg)
Protective factors
• Multiparity: First pregnancy before age 30• Oral contraceptives: 5 years of use cuts risk nearly
in half• Tubal ligation• Hysterectomy• Bilateral oopherectomy -↓ risk by 80% to 95%• Lactation• Epidemiologic and laboratory evidence suggest a
potential role for retinoids, vitamin D, NSAIDs as preventive agents for ovarian cancer
![Page 17: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/17.jpg)
• Role of ovulation (repetitive process of DNA damage,
inflammation, and repair of the surface epithelium) in the pathogenesis of the malignancy
• Epithelial ovarian neoplasms are thought to arise from the surface epithelium covering the ovary.
• As repair follows multiple ovulations, the surface epithelium of the ovary often extends into the ovarian stroma to form inclusion glands and cysts.
PATHOGENESIS
![Page 18: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/18.jpg)
• The epithelium, via neoplastic transformation, may exhibit differentiation toward a variety of müllerian-type cells– serous fallopian tubal lining– mucinous
• Intestinal gastrointestinal mucosa
• Müllerian endocervix
– Endometrioid endometrial glands
– Brenner/transitional bladder– clear cell mesonephric (renal
cell)
![Page 19: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/19.jpg)
• Ovarian carcinogenesis can be divided into two broad phases:
– malignant transformation• Benign borderline malignant ovarian tumors.
– peritoneal dissemination.
• Now do not appear to be valid for the majority of ovarian cancers
![Page 20: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/20.jpg)
New model of ovariancarcinogenesis
• Surface epithelial tumors divides into two broad categories: Type I and Type II
– based on their clinicopathologic features and characteristic molecular genetic changes
![Page 21: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/21.jpg)
Type I
• Low grade• Arise from precursor lesion
in a stepwise fashion– Cystadenoma– Borderline tumor
• Typically present in stage I• Slow growing, indolent• Often remains low grade• E.g.
– Low grade micropapillary– Mucinous– Clear cell– endometroid
Type II
• High grade• Arise “de novo”
• Typically present in advanced stage
• Rapid growing, aggressive• E.g.
– High grade serous – MMMT
![Page 22: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/22.jpg)
• Molecular biologic evidence supports dualistic
model of ovarian carcinogenesis.
– High-grade serous carcinomas p53 mutations
– low grade serous carcinomas mutations in K-ras
and BRAF genes.
• Pten mutations in endometrioid tumors and K-ras in
mucinous tumors also supports the stepwise
progression model.
![Page 23: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/23.jpg)
• Very recently, Lee et al. have proposed – many high-grade serous carcinomas actually arise
in the mucosa of the fimbriated end of the fallopian tube.
![Page 24: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/24.jpg)
Pathologic Classification
• Surface epithelial – 65-70%
• Germ cell tumors – 15-20%
• Stromal– 5-10%• Metastatic tumors –
5%
![Page 25: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/25.jpg)
1.Surface epithelial tumors1. Serous tumors2. Mucinous tumors
1. Endocervical-like2. Intestinal type
3. Endometrioid tumors4. Clear cell tumors5. Transitional cell tumors6. Squamous cell tumors7. Mixed epithelial tumors8. Undifferentiated and unclassified carcinoma
2.Sex cord-stromal tumors1. Granulosa-stromal cell tumors
1. Granulosa cell tumors (adult and juvenile)2. Tumors in the thecoma—fibroma group
1. Thecoma2. Fibroma3. Cellular fibroma4. Fibrosarcoma5. Sclerosing stromal tumor
2. Sertoli/stromal-cell tumors1. Sertoli cell tumors2. Sertoli-Leydig cell tumors
3. Sex cord tumors with annular tubules4. Gynandroblastoma5. Unclassified6. Steroid (lipid) cell tumors
1. Stromal luteoma2. Leydig cell tumor3. Steroid cell tumor, not otherwise specified
3. Germ cell tumors1. Dysgerminoma2. Yolk sac tumor (endodermal sinus tumor)3. Embryonal carcinoma4. Polyembryoma5. Choriocarcinoma6. Teratoma
1. Immature2. Mature3. Struma ovarii4. Carcinoid tumors
7. Mixed germ cell tumors4. Gonadoblastoma5. Miscellaneous
8. Small cell carcinoma9. Malignant lymphomas, leukemias,
plasmacytomas10. Unclassified11. Metastatic tumors
World Health Organization Histologic Classification of Ovarian Neoplasms
![Page 26: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/26.jpg)
Surface Epithelial tumors
• Serous (tubal) • Mucinous (endocx & intestinal)• Endometrioid• Transitional cell - Brenners.• Clear cell
![Page 27: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/27.jpg)
Surface Epithelial tumors
All types can be benign, borderline , or malignant, depending upon;
• Benign ;- – gross: mostly cystic – microscopic; fine papillae, single layer covering (no stratification), no
nuclear atypia, no stromal invasion)• Borderline ; -
– gross; cystic / solid foci – microscopic; papillary complexity, stratification, nuclear atypia, no
stromal invasion• Malignant ; -
– gross; mostly solid & hemorrhage / necrosis– microscopic; papillary complexity, stratification, nuclear atypia,
stromal invasion
![Page 28: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/28.jpg)
Serous Tumors:
• Frequently bilateral (30-66%).
• 75% benign/bord., • 25% malignant.• Tall columnar ciliated
epithelium.
![Page 29: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/29.jpg)
Serous Cystadenoma
• Single layer of ciliated columnar
•Fine papillae
Papillary cystadenoma (bor) •Papillary complexity
•Nuclear stratification& atypia
•No stromal invasion
![Page 30: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/30.jpg)
Serous cystadenocarcinoma
• Papillary complexity• Nuclear stratification & atypia• stromal invasion• Psammoma bodies• Often associated with CA 125 elevation.
![Page 31: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/31.jpg)
Mucinous Tumors:
• Less common 25%, very large.
• Rarely malignant - 15%.• Multiloculated, many small
cysts.• Rarely bilateral – 5-20%.• Tall columnar, apical mucin.• Pseudomyxoma peritonei.
![Page 32: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/32.jpg)
Mucinous cystadenoma
•Multilocular cyst lined by single layer of columnar cells with basally placed nuclei and apical mucin.
Mucinous cystadenoma-borderline•Papillary complexity•Nuclear stratification& atypia• No stromal invasion
![Page 33: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/33.jpg)
Mucinous cystadenocarcinoma •Papillary complexity•Nuclear stratification& atypia•stromal invasion
•CA 125 levels may not be markedly elevated. •Relatively chemoresistant.• sim. Clear cell ca also.
• Differential diagnosis of a mucinous ovarian tumor includes metastatic disease from an appendiceal primary.
![Page 34: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/34.jpg)
Endometrioid tumors
• most are unilateral (40% are bilateral)
• almost all are malignant• many are associated
with endometrial cancer (30%)
• patient may have concurrent endometriosis
![Page 35: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/35.jpg)
Endometrioid adenocarcinoma
• stromal invasion by irregular malignant endometrial glands
![Page 36: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/36.jpg)
![Page 37: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/37.jpg)
Primary tumor (T)TNM FIGO
T1 I Tumor limited to the ovaries (1 or both)T1a IA Tumor limited to 1 ovary; capsule intact, no tumor on ovarian surface; no malignant cells in
ascites or peritoneal washings
T1b IB Tumor limited to both ovaries; capsules intact, no tumor on ovarian surface; no malignant cells in ascites or peritoneal washings
T1c IC Tumor limited to 1 or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings
T2 II Tumor involves 1 or both ovaries with pelvic extensionT2a IIA Extension and/or implants on the uterus and/or tube(s); no malignant cells in ascites or
peritoneal washings
T2b IIB Extension to other pelvic tissues; no malignant cells in ascites or peritoneal washings
T2c IIC Pelvic extension (T2a or T2b) with malignant cells in ascites or peritoneal washingsT3 III Tumor involves 1 or both ovaries with microscopically confirmed peritoneal metastasis outside
the pelvis
T3a IIIA Microscopic peritoneal metastasis beyond the pelvis (no macroscopic tumor)T3b IIIB Macroscopic peritoneal metastasis beyond the pelvis ≤ 2 cm or less in greatest dimension
T3c IIIC Macroscopic peritoneal metastasis beyond the pelvis > 2 cm in greatest dimension and/or regional lymph node metastasis
TNM and FIGO staging for Ovarian Cancer
![Page 38: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/38.jpg)
Regional lymph nodes (N)TNM FIGO
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 IIIC Regional lymph node metastasisDistant metastasis (M)TNM FIGO
M0 No distant metastasis
M1 IV Distant metastasis (exclude peritoneal metastasis)
![Page 39: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/39.jpg)
Stage I ovarian cancer• limited to the ovaries.
– Stage IA: tumour limited to 1 ovary, the capsule is intact, no tumour on ovarian surface and no malignant cells in ascites or peritoneal washings.
– Stage IB: tumour limited to both ovaries, capsules intact, no tumour on ovarian surface and no malignant cells in ascites or peritoneal washings.
– Stage IC: tumour is limited to 1 or both ovaries with any of the following: capsule ruptured, tumour on ovarian surface, malignant cells in ascites or peritoneal washings.
![Page 40: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/40.jpg)
Stage II ovarian cancer• tumors involving 1 or both ovaries
with pelvic extension and/or implants. – Stage IIA: extension and/or
implants on the uterus and/or fallopian tubes. No malignant cells in ascites or peritoneal washings.
– Stage IIB: extension to and/or implants on other pelvic tissues. No malignant cells in ascites or peritoneal washings.
– Stage IIC: Pelvic extension and/or implants (stage IIA or stage IIB) with malignant cells in ascites or peritoneal washings.
![Page 41: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/41.jpg)
Stage III ovarian cancer• tumours involving 1 or both ovaries
with microscopically confirmed peritoneal implants outside the pelvis. Superficial liver metastasis equals stage III.
• – Stage IIIA: microscopic
peritoneal metastasis beyond pelvis (no macroscopic tumour).
– Stage IIIB: macroscopic peritoneal metastasis beyond pelvis less than 2 cm in greatest dimension.
– Stage IIIC: peritoneal metastasis beyond pelvis greater than 2 cm in greatest dimension and/or regional lymph node metastasis.
![Page 42: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/42.jpg)
Stage IV ovarian cancer Tumours involving 1 or both ovaries with distant metastasis.
Parenchymal liver metastasis equals stage IV.
![Page 43: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/43.jpg)
Metastasis • Typical spread– omentum, peritoneal surfaces such as
undersurface of diaphragm, paracolic gutters and bowel serosa
• Lymphatics– follows bld supply thru infundibulopelvic lig to nodes in para aortic region
• Drainage thru broad lig and parametrium– involves ext iliac, obturator and hypogastric regions
• Along round lig– involves inguinal nodes
• Extra abd mets– pleura, liver , spleen, lung, bone and CNS
![Page 44: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/44.jpg)
Ovarian Cancer
![Page 45: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/45.jpg)
Diagnosis and Clinical Evaluation
• ̴��75% to 85% of patients with epithelial ovarian cancer are diagnosed at the time when their disease has spread throughout the peritoneal cavity.
![Page 46: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/46.jpg)
Symptoms of ovarian cancer
• Asymptomatic• Vague new and frequent (>12days/month)
symptoms of – bloating, – Abdominal enlargement– pelvic or abdominal pain, – difficulty eating, or early satiety, – Vaginal bleeding– or urinary urgency or frequency.
![Page 47: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/47.jpg)
Diagnostic tools
History• Pelvic Exam (including rectal)• Transvaginal Ultrasound • Tumor markers• CT • MRI
![Page 48: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/48.jpg)
Exam
• Physical– Malignancy: irregular
margins, solid consistency, is fixed, nodular, or bilateral, is associated with ascites
![Page 49: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/49.jpg)
Physical examination
In menstruating women only 5-18% of adnexal masses will prove malignant vs. postmenopausal women 30-60% of masses will be malignant.
![Page 50: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/50.jpg)
So if you find a mass…what else can it be???
• Endometrioma• Fibroid• Functional cyst • Ectopic pregnancy• Dermoid tumor (younger women)
![Page 51: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/51.jpg)
Ultrasound
• Initial imaging modality of choice – for benign vs malignant
• Results of screening trials have consistently demonstrated that US detects more stage I ovarian carcinomas than CA125 levels and physical examination
• very few stage I carcinomas have been found
![Page 52: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/52.jpg)
• near 95% to 99% NPV in excluding malignancy
• benign :- smooth, thin walls; few, thin septations; absence of solid components or mural nodularity.
• mural nodules, mural thickening or irregularity, solid components, thick septations (3 mm) and associated findings such as ascites, peritoneal implants, and/or hydronephrosis suggest malignancy
• use of color and pulse Doppler in the evaluation of ovarian masses is controversial
![Page 53: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/53.jpg)
TVS vs Pelvic Exam
Ueland, DePriest, DeSimone, Pavlik, Lele, Kryscio, van Nagell JR Jr. The accuracy of examination under anesthesia and transvaginal sonography in evaluating ovarian size. Gynecol Oncol. 2005 Nov;99(2):400-3.
TVS is significantly more accurate (p< 0.001)
Detection TVS PE N =
Overall 85% 44% 289
> 55 yrs 74% 30% 88
> 200 lbs 73% 9% 66
> 200 gram ut 80% 16% 74
![Page 54: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/54.jpg)
You found a mass…what next…
It’s reasonable to follow a mass IF… The mass is not suspicious on ultrasound
- (ie the mass is mobile, looks like a simple cyst, is less than 8-10cm)
- The mass should resolve over 2 mos or otherwise patient should have surgery.
- The threshold is lower for post menopausal women…surgery if their cyst is > 5 cm.
![Page 55: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/55.jpg)
• In postmenopausal and asymptomatic, with unilateral simple cyst <5cm AND normal CA- 125, can follow closely with repeat TVUS
• All other postmenopausal women with ovarian mass require surgical evaluation
![Page 56: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/56.jpg)
Computed Tomography
• Not the study of choice to evaluate a suspected ovarian lesion.
• the sensitivity, specificity, and accuracy of CT for characterizing benign versus malignant lesions are reported to be 89%, 96% to 99%, and 92% to 94%, respectively.
![Page 57: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/57.jpg)
• On CT, ovarian cancer demonstrates varied morphologic patterns, including a multilocular cyst with thick internal septations and solid mural or septal components, a partially cystic and solid mass, and a lobulated, papillary solid mass.
![Page 58: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/58.jpg)
Magnetic Resonance Imaging
• Complementary to US in the evaluation of a suspected ovarian lesion.
• As with CT, disease metastatic to the ovary is often indistinguishable from primary ovarian cancer on MRI scans
• both the colon and the stomach should be examined as potential primary tumor sites if an ovarian mass is detected.
![Page 59: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/59.jpg)
• Several studies have compared MRI to CT and US for characterizing adnexal masses, with mixed results
• Both TVS and MRI have high sensitivity (97% and 100%, respectively) in the identification of solid components within an adnexal mass. – MRI, however, shows higher specificity (98% vs.
46%)
![Page 60: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/60.jpg)
• MRI was shown to be the most efficient second test when an indeterminate ovarian mass was detected at gray-scale US.
• high cost of MRI precludes its use as a screening modality.
• The additional use of FDG-PET has been
shown to be extremely useful and should be considered as an adjunct to, rather then a replacement for, conventional imaging.
![Page 61: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/61.jpg)
Positron Emission Tomography
• little clinical role in the primary detection of a pelvic mass
• Appears to be promising for – its potential to detect tumor prior to significant
morphologic changes.
• Specifically, the sensitivity, specificity, accuracy, PPV, and NPV of FDG-PET were 83%, 80%, 82%, 86%, and 76%, respectively.
![Page 62: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/62.jpg)
• US, CT, MRI, and FDG-PET all have a role to play in the accurate staging of ovarian cancer.
• These modalities also play a role in the monitoring of therapy and detection of recurrent disease.
![Page 63: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/63.jpg)
Tumor Markers
• CA125– an antigenic determinant on a high-molecular-weight
glycoprotein recognized by the murine monoclonal antibody OC-125.
– upper limit of normal- 35 U/mL.– In postmenopausal women :- lower cutoffs, 20 U/mL.
– 85% of patients with epithelial ovarian cancer have >35 U/mL.
• in 50% of patients with stage I disease,• >90% of patients with advanced disease.
![Page 64: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/64.jpg)
• CA125 can be elevated – less frequently elevated in mucinous, clear cell, and
borderline tumors compared to serous tumors.
– in other malignancies (pancreas, breast, colon, and lung cancer) and
– in benign conditions and physiological states such as pregnancy, endometriosis, and menstruation.
– Many of these nonmalignant conditions are not found in postmenopausal women, improving the diagnostic accuracy of elevated CA125 in this population.
![Page 65: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/65.jpg)
ROCA: Risk of Ovarian Cancer Algorithm
• CA125 was initially interpreted using a fixed cutoff. • Sensitivity and specificity has been improved by the development of a statistical algorithm• When the ROC algorithm was applied, the area under the curve was significantly improved in comparison to a fixed CA125 cutoff (93% vs. 84%)
![Page 66: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/66.jpg)
• One of the limitations of CA125 is that 15% to 20% of ovarian cancers do not express the antigen.
• Several other markers studied• Human epididymis protein 4• Mesothelin• B7-H4• Decoy receptor 3• Spondin 2
– Neither of these is useful.
• Though FDA approved, NCCN does not recommend use of biomarkers including CA-125 for estimating risk of cancer in case of pelvic mass.
![Page 67: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/67.jpg)
Tumor Markers
• LDH (lactate dehydrogenase)—dysgerminoma
• HCG (human chorionic gonadotropin)– choriocarcinoma.
• AFP (alpha fetal protein)-- endodermal sinus tumors
![Page 68: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/68.jpg)
• FNA should be avoided.
• May be necessary, if bulky disease not surgical candidates.
• CBC, LFT, KFT• Chest X-ray
![Page 69: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/69.jpg)
Screening
• 5-year survival rates for – stage I and stage II ovarian cancer are 80% to 90%
and 70%, respectively ; – for stages III and IV ranges from 5% to 30%.
• Only 25% diagnosed in Stage I
![Page 70: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/70.jpg)
• In 1994, a NIH consensus conference recommended that screening be offered to women with ≥2 first-degree relatives with ovarian carcinoma.
• In practice, many women with a single first-degree relative are enrolled in screening programs.
![Page 71: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/71.jpg)
• Unfortunately, there are no good screening methods for ovarian cancer at present; – most use a combination of physical exam, CA125 levels, and
TVS.
• PLCO Cancer Screening Trial demonstrated that the PPV value for invasive cancer was – 1.0% for an abnormal TVS, – 3.7% for an abnormal CA125, and – 23.5% if both tests (CA125 and TVS) were abnormal.– But screening with TVS and CA-125 did not dec. mortality
• Only one study has demonstrated ovarian cancer screening trials to have a survival benefit.
» Van Nagell JR Jr, et al.. Cancer 2007;109(9):1887–1896.
![Page 72: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/72.jpg)
• No role of routine screening in general population
• Some follow women with high risk factors (e.g., family history, BRCA mutation) using CA-125 and TVS.
![Page 73: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/73.jpg)
Risk of Malignancy Index (RMI)
• Most valuable clinical tool by combining serum CA125 values with ultrasound findings and menopausal status to calculate a Risk of Malignancy Index (RMI).
• RMI = U x M x CA125– ultrasound result is scored 1 point for each of the following
characteristics: multilocular cysts, solid areas, metastases, ascites and bilateral lesions.
– menopausal status is scored as 1 = pre-menopausal and 3 = post-menopausal
– Serum CA125 in IU/ml and can vary between 0 and hundreds or even thousands of units.
• It yielded a sensitivity of 85% and a specificity of 97%.
![Page 74: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/74.jpg)
• OVA1 is an FDA-cleared blood test that uses results of 5 biomarkers (transthyretin, apolipoprotien
A1, transferrin, beta-2 microglobin and CA-125), with an algorithm to indicate the probability of malignancy of an ovarian mass.
• OvaSure screening test- 6 biomarkers• Leptin, prolactin, osteopontin, IGFII, MIF and CA-125.
• not recommended.
![Page 75: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/75.jpg)
Management
![Page 76: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/76.jpg)
Treatment for Newly Diagnosed Ovarian Cancer
• Complete surgical staging
• Optimal reductive surgery
• Chemotherapy
• Clinical Trials
![Page 77: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/77.jpg)
• Complete surgical staging– Full assessment of abdomen and pelvis– Random biopsy of visually negative areas– Lymph node dissection (except Stage I)
• Optimal reductive surgery• Chemotherapy• Clinical Trials
![Page 78: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/78.jpg)
Vertical incision Multiple cytologic washings Random peritoneal biopsies, including diaphragm TAH and BSO
USO in stage IA or IC Intact tumor removalOmentectomy Complete abdominal exploration Lymph node sampling
Surgical Staging of Ovarian Cancer
![Page 79: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/79.jpg)
The State of Treatment for Newly Diagnosed Ovarian Cancer
• Complete surgical staging• Optimal reductive surgery
– Stage I, II - Complete removal of all disease– Stage III, IV - Residual disease < 1 cm
• Chemotherapy• Clinical Trials
![Page 80: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/80.jpg)
Optimal Cytoreduction
0 cm
0-1 cm1-2 cm>2 cm
Time since initial surgery (years)
Prop
ortio
n su
rviv
ing
![Page 81: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/81.jpg)
• Procedures that may be considered for optimal surgical cytoreduction :-– Radical pelvic dissection– Bowel resection– Diaphragm or other peritoneal surface stripping– Splenectomy– Partial hepatectomy– Cholecystectomy– Partial gastrectomy or cystectomy– Or distal pancreatectomy
![Page 82: Ca ovary dr. varun](https://reader033.vdocument.in/reader033/viewer/2022061111/5455d2d4af7959664b8b76b2/html5/thumbnails/82.jpg)
THANK YOU…